https://www.selleckchem.com/pr....oducts/ll37-human.ht
001). Serum IFN-λ3 levels showed negative correlation with HBsAg reduction in ADV/TDF group (r = -0.386, p = 0.038) at week 48. Nucleotide analogs (ADV/TDF) treatment has associated factors with -0.3 log HBsAg decline at 1year, -0.5 log HBsAg decline at 3years, and -0.8 log HBsAg decline at 5years after NAs treatment on multivariate analysis. Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction. Nucleotide analog (ADV/TDF) treatment reduced HBsAg le
Respect!
Kommentar
Delen
